Table 1

Demographics for the exploration panel and the validation panel

Exploration panelValidation panelPSC E versus VHC E versus V
PSC (N=41)HC (N=124)p ValuePSC (N=44)HC (N=139)p Valuep Valuep Value
Age, median years (min–max)50.0 (23–82)46.0 (31–61)0.1248.0 (21–69)47.0 (30–61)0.150.940.40
Sex, male (%)24 (58.5)51 (41.1)0.0729 (65.9)57 (41.0)<0.010.511.00
BMI, median kg/m2 (min–max)25.5 (18–37)25.9 (18–39)0.8624.4 (18–38)25.5 (19–43)0.170.800.61
Smoking, yes (%)1 (2.4)17 (13.7)<0.051 (2.3)13 (9.4)0.191.000.33
Sample time in RT, median hours (min–max)27.0 (15–63)32.0 (18–72)0.5127.5 (13–59)34.0 (16–71)0.281.000.65
Courses of AB <12 months, median (min–max)0 (0–7)0 (0–5)0.180.0 (0–10)0 (0–3)0.790.150.82
UC, n (%)19 (46.3)25 (56.8)0.39
Crohn's disease, n (%)8 (19.5)3 (6.8)0.11
Medication, yes, n (%)
 PPI4 (9.8)12 (9.7)1.002 (4.5)6 (4.3)1.000.420.09
 Antihistamines2 (4.9)8 (6.5)1.004 (9.1)6 (4.3)0.260.680.58
 Statins3 (7.3)5 (4.0)0.414 (9.1)6 (4.3)0.261.001.00
 Ursodeoxycholic acid13 (31.7)12 (27.3)0.81
 Prednisolon4 (9.8)9 (20.5)0.23
 5-ASA19 (46.3)16 (36.4)0.39
 Infliximab1 (2.3)1.00
 Azathioprine4 (9.8)8 (18.2)0.36
 Budesonide2 (4.9)1 (2.3)0.61
Disease-specific variablesAvailable for
 PSC disease duration, median years (min–max)10.6 (1–32)6.6 (1–26)0.12N=85
 IBD duration, median years (min–max)10.3 (0–41)11.9 (2–45)0.95N=63
 Other autoimmune diseases, yes (%)12 (29.3)11 (25.0)0.63N=80
 Mayo risk score, median (min–max)−0.04 (−1.5–3.2)−0.06 (−1.9–3.3)0.98N=64
 P-ANCA status, positive (%)21 (51.2)23 (52.3)0.65N=77
 Platelet count, 109/L, median (min–max)210 (57–578)256 (62–432)<0.05N=77
 Creatinine, µmol/L, median (min–max)69 (42–106)68 (42–100)0.98N=78
 Bilirubin, µmol/L, median (min–max)13 (5–101)13 (3–114)0.61N=77
 Albumin, g/L, median (min–max)43 (24–47)43 (16–47)0.26N=72
 INR, median (min–max)1.0 (0.9–1.3)1.0 (0.9–1.3)0.44N=68
 AST, U/L, median (min–max)59 (19–197)43 (18–172)0.49N=72
 ALT, U/L, median (min–max)59 (14–331)48 (14–320)0.66N=78
 ALP, U/L, median (min–max)178 (50–598)142 (30–589)0.40N=77
 GGT, U/L, median (min–max)201 (10–1576)175 (12–1091)0.86N=76
  • AB, antibiotics; ALP, alkaline phosphatase; ALT, alanine aminotransferase; 5-ASA, 5-Aminosalicylic acid; AST, aspartate aminotransferase; BMI, body mass index; E, exploration panel; GGT, gamma-glutaryltransferase; HC, healthy controls; INR, international normalised ratio; P-ANCA, perinuclear anti-neutrophil cytoplasmic antibodies; PPI, proton pump inhibitors; PSC, primary sclerosing cholangitis; RT, room temperature; V, validation panel.